The promise of IL-1β modulation in NSCLC clinical context
Emerging preclinical evidence challenges the long-standing assumption that Interleukin-1β (IL-1β) uniformly promotes non–small cell lung cancer (NSCLC). We show that, in the context of chemo-immunotherapy, IL-1β enhances anti-tumor immunity by inducing tumor-cell CXCL10 expression and recruiting CD8...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2026-01-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1773253/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|